Health Care [ 5/12 ] | Biotechnology [ 39/75 ]
NASDAQ | Common Stock
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States.
The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage.
It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California; a co-development and distribution agreement with Newsoara Biopharma Co., Ltd; and a transformative strategic collaboration with Strand Life Sciences for advancing precision medicine for ulcerative colitis therapy.
The company is based in Carlsbad, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 7, 24 | -2.32 Decreased by -428.18% | -3.35 Increased by +30.63% |
| Aug 9, 24 | -3.32 Decreased by -526.42% | -2.93 Decreased by -13.31% |
| May 13, 24 | -4.59 Decreased by -750.00% | -4.80 Increased by +4.38% |
| Mar 26, 24 | -6.45 Decreased by -199.69% | -5.17 Decreased by -24.76% |
| Nov 9, 23 | -0.44 Increased by +89.00% | -0.39 Decreased by -12.82% |
| Aug 11, 23 | -0.53 Increased by +91.17% | -0.45 Decreased by -17.78% |
| May 11, 23 | -0.54 Increased by +95.85% | -0.72 Increased by +25.00% |
| Mar 22, 23 | 6.47 Increased by +61.75% | -2.43 Increased by +366.26% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | N/A Decreased by N/A% | -3.49 M Increased by +3.03% | - - |
| Jun 30, 24 | 0.00 Decreased by N/A% | -4.08 M Decreased by -20.25% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by -100.00% | -3.53 M Decreased by -63.97% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | -250.00 K Decreased by N/A% | -2.97 M Decreased by -10.82% | Increased by +1.19 K% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -3.60 M Decreased by -0.87% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -3.39 M Decreased by -204.03% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 250.00 K Increased by +N/A% | -2.15 M Increased by +52.43% | Decreased by -860.40% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by N/A% | -2.68 M Decreased by -349.86% | Decreased by N/A% Decreased by N/A% |